Calendar

Date Time Place Information
October 25, 2021
Karolinska Institutet Stockholm
KI PCM Program evaluation
The PCM program will be evaluated by a committee of three international reviewers.
December 18, 2020
15:00
PCM steering group meeting

See older events

Date Time Place Information
November 3, 2020
09:00
Zoom
CCE 2020 edition of the Annual Meeting
The 2020 edition of the Annual Meeting, organised this year by the Istituto Nazionale dei Tumori and originally scheduled to take place in early April, will take place in an online format via Zoom, on November 3rd, 2020 from 9am to 3pm. The detailed agenda is currently being finalised - the main topics which will be discussed during this virtual meeting are: The new structure of CCE and its short- and long-term operational strategy; The overview of CCE’s research activities and its response to the covid-19 situation; The network’s three new main development pillars : a clinical trials strategy, the creation of a virtual data centre, and our education & training programs. Each of these presentations will be followed by ample time for a Q&A session and interaction with the speakers and PIs of the various activities of the consortium. In order to participate, registration is mandatory through the following link - https://www.weezevent.com/cce-virtual-annual-meeting ; the current deadline for registration is set for October 23rd, 2020. Should you have any question or need assistance with your registration, please feel free to reach out to giovanni.scoazec@istitutotumori.mi.it and costanza.bono@istitutotumori.mi.it, and feel free to circulate this information to interested colleagues in your departments as well !
October 9, 2020
13:00
CCK building, level 5
PCM steering group meeting
Welcome to the first PCM steering group meeting for the autumn. We particularly welcome new members Karin Ekström Smedby, Päivi Östling and Eskil Degsell. Meanwhile to the working group has been very active with several meetings. Preliminary points on the agenda: 1. International evaluation of PCM, March 25-26 2021. 2. Clinical trial task force; Workshop February; an update on BoB-trial. 3. iPCM. Sequencing/transcriptomics of all advanced/metastatic cancers. 4. Action upon PCM DNA diagnostics. Report on PePaCaKa. Trial with new/repurposed drugs? 5. PPPCCM 6. KIs Precision Medicine initiative chaired by Anna Martling. 7. Data sharing 8. Cancer Core Europé updates 9. Budget follow up 10. Reports - Meeting with Björn Zoega - Home page - Education - Others 11. Next meeting Tuesday December 15 at 15.00
July 6, 2020
16:00
New paper in Nature Medicine by David Tamborero
Today, the paper by Tamborero, Dienstmann et al. "Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal" is published in Nature Medicine. This work describes the use of a new precision cancer medicine technology to inform the use of individualised treatments in clinical trials guided by the genomics profile of the tumours. The portal has been developed at Karolinska Institutet and SciLifeLab together with clinical researchers from seven European comprehensive cancer centre enters and has currently analysed more than 500 patients' samples. Our current ability to profile the molecular characteristics of tumours has opened the door to more effective therapies tailored to each patient's disease. However, this has also brought new challenges to the medical teams, which must interpret the gene alterations detected in the patient's tumour and select the most appropriate treatment according to the latest scientific evidence. This process is complicated and time-consuming, and often requires the use of databases and computational tools that are not readily accessible at the clinical setting. As the number of molecular biomarkers continues to grow, the use of new technologies to facilitate genomics data interpretation and knowledge exchange are needed for treatment planning. In response, the Lehtiö lab has developed the Molecular Tumor Board Portal. This clinical decision support system combines a variety of state-of-the-art methods to classify the actionability of genomic tumour alterations and inform clinical interventions. This portal is currently used by a collaborative network of seven European comprehensive cancer centres, which includes the Karolinska University Hospital, under the umbrella of the Cancer Core Europe. The portal has analysed more than five hundred patients in the context of the Basket of Baskets trial (NCT03767075), a multi-arm study for genomically-defined tumours that do not respond to standard-of-care therapies. This experience is published today in Nature Medicine. "The portal automates the data interpretation, which eliminates potential errors due to manual processes and provides a systematic analysis based on expert consensus criteria", says David Tamborero, senior researcher at Karolinska Institutet SciLifeLab, and leading scientist of the project; "The use of this platform also avoids delays in the delivery of the results, which is critical for patients whose condition may rapidly deteriorate". The portal provides the framework to share the results via patient-centric reports accessible in a secure, web-based application. These reports are data-rich interactive documents discussed during weekly virtual meetings, in which multidisciplinary representatives from each Cancer Core Europe centre agree on clinical actions. "From an oncologist view, the system has changed how we work. By using the portal in molecular tumor boards we have easy access to the latest knowledge on cancer mutations and can discuss the cases with colleagues from all the seven centres in a truly collaborative manner", says Rodrigo Dienstmann, Principal Investigator of the Oncology Data Science Group of the Vall d'Hebron Institute of Oncology. The authors describe a learning curve to use the technology lasting for approximate twenty-five reviewed patients. After that, the amount of time devoted to discussing each case rarely exceeds a few minutes, which is critical to scale the data-driven decision process to a large number of patients. As a resource to investigators outside of the Cancer Core Europe network, an open access version of the Molecular Tumor Board Portal genomics interpretation pipeline has been made available at https://mtbp.org. "We believe that the use of the portal in the clinical setting is key to accelerate the translation of new research discoveries to the patients' benefit", says Janne Lehtiö, professor at Karolinska Institutet and scientific director of SciLifeLab. "We are currently working to incorporate data from emerging biomarkers such as proteomics and digital pathology in the portal "further to improve the selection of the treatment for each patient.
March 25, 2019
VHIO Barcelona
4th Annual meeting of Cancer Core Europe
The 4th Annual meeting of Cancer Core Europe takes place in Barcelona, beteen March 25-26. The 2019's agenda will focus on the Cancer Core Europe work and projects, and include task force presentations with discussions where everyone can contribute, as well as cross task force discussions and project specific gatherings.
October 1, 2019
13:00
Campus Solna Biomedicum D1012, 10th floor, Solnavägen 9, Campus Solna
Cell and Tumour Biology Seminar: From conventional Cancer treatment to Precision Cancer Medicine (PCM) and beyond